The FLAV4AMR project was approved under the sixth call of the European JPIAMR program.
Antimicrobial resistance is responsible for 33,000 deaths annually in the European Union, and the costs of medical care and productivity losses are estimated in 1.5 billion euros. In this context, Helicobacter pylori has been identified by the WHO as one of the pathogens for which it is urgent to find new antibacterial compounds, due to the high incidence of antibiotic-resistant strains. H. pylori is responsible for the most common infection among the world’s population leading to chronic gastritis that can evolve to ulcer diseases but also gastric cancer. It is well now recognized that H. pylori is a major risk factor for gastric cancer development, thus highlighting the need of efficient treatment of eradication for this bacterium.
The objectives of this project are to develop new ﬂavodoxin inhibitors having significant antimicrobial activity, both for H. pylori and for other pathogens due to the significant increase of their antibiotic resistance.
Composition of the research consortium and expertise:
1. BIFI-University of Zaragoza, Spain
Javier SANCHO – Biochemistry: compound design, clinical chemistry of compounds (Principal Investigator) José Antonio Aínsa – Microbiology
2. Institut Pasteur, Paris, France
Eliette TOUATI – Gastric cancer research: mouse model of Hp infectio
3. Research Center Borstel, Germany
Ulrich E. SCHAIBLE – Microbiology: microbiome analysis, host pathogen interaction and tests on the ESKAPES group of multidrug resistant pathogens. Dominik SCHWUDKE – Bioanalytical chemistry: PK / PD measurements with LC-MS/MS
4. École Nationale Vétérinaire (INRA) Toulouse, France
Alain BOUSQUET-MELOU– Pharmacology: modelling of PK / PD in vitro